| career opportunities | our spirit and values |
Addex Theurapeutics is a matrix organization where Biology and Chemistry units provide the necessary support to the different ongoing projects in various therapeutic areas, which include Central Nervous System, Inflammation and Metabolism. Non-Clinical Development and Clinical Development departments advance the most promising molecules into clinical testing.
Addex will consider candidates interested in a unique opportunity for long-term professional and personal development. Our standards are high and our employees demand a lot from themselves. Addex provides an exciting environment and a challenging place to work, where you can see your contributions make a difference. We offer salaries commensurate with applicants' competencies. We are an equal opportunity employer.
We currently have an no open position, if you wish to apply spontaneously please send your application to Addex HR.
- ADX71441 produced dose-dependent changes on growth hormone (GH) plasma concentrations in a preclinical model
- The data confirms the role of gamma-aminobutyric acid (GABA) in modulating GH plasma concentrations...
• Dose-dependent receptor occupancy correlates with plasma exposure and links to efficacy in non-human primate model of Parkinson’s Disease levodopa-induced dyskinesia
• Data reinforces Phase 2a pharmacological...
Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role
Geneva, Switzerland, 30 April 2013 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Co-Founder and Chief...
Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence
• Data reinforces broad therapeutic potential of ADX71441, an oral GABAB receptor Positive Allosteric Modulator
• Recent approval of Clinical Trial Application (CTA) to initiate a Phase 1, first–in-man,...
Addex Receives Approval to Initiate a Phase 1, First–In-Man, Clinical Study for ADX71441
ADX71441, a novel oral small molecule GABA-B receptor positive allosteric modulator, on track to initiate clinical testing in first half of 2013 and to deliver top-line safety, PK and biomarker data by year...
Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant
Dipraglurant, an mGlu5 negative allosteric modulator, in clinical development for levodopa-induced dyskinesia as well as certain rare dystonias
Geneva, Switzerland, 22 April 2013 – Addex Therapeutics (SIX:ADXN),...
Dipraglurant, an mGlu5 negative allosteric modulator, currently in Phase 2 studies for levodopa-induced dyskinesia is on track for start of Phase 2 studies in rare dystonias in the first half of...
$1 MM grant by The Michael J. Fox Foundation to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia
Geneva,...
Addex Shareholders Approve All Board Proposals at Annual General Meeting
Geneva, Switzerland, 20 March 2013 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its...
Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research
Grant to be used to help fund further human clinical testing of dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia
<link...
Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor
Partnership to demonstrate the potential to accelerate the development of allosteric modulator-based therapeutics against GPCRs by integrating proprietary functional and structural biology...
Addex Therapeutics Reports 2012 Financial Results
2012 Financial Highlights ...
Addex to Focus Resources on Clinical Pipeline
2013 Value Drivers:
• Initiate Phase 2 clinical testing of dipraglurant (mGlu5 NAM) in a rare disease indication
• Submit Orphan Drug Application in U.S. and Europe for dipraglurant<br...
Dipraglurant, a novel oral small molecule negative allosteric modulator of mGlu5 receptor, on track for Phase 2 clinical testing in the second half of 2013
Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441
ADX71441, a novel oral small molecule positive allosteric modulator of GABA-B receptor, on track for Phase 1 clinical testing in the first half of 2013
Allostery: Key to addressing important unmet needs in CNS diseases
Addex'high throughput allosteric drug discovery platform is paving the way for a new approach to cracking "undruggable" therapeutic targets.
Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Alcohol Binge Drinking
- Data reinforces broad therapeutic potential of oral ADX71441
-
Geneva, Switzerland, 12 October...
Dyskinesia: Hope on the Horizon
Grant to Further Characterize Allosteric Modulators Against mGluR4 and mGluR7
Geneva, Switzerland, 2 October 2012 –
Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model
A Novel Oral Small Molecule Approach for the Treatment of Multiple Sclerosis
Geneva, Switzerland, 24 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering...
Soutien américain au biotech à Genève
ADDEX.Le titre a bénéficié d'un regain d'intérêt des investisseurs outre-Atlantique.
La direction plaide encore la sous-évalutation.
Geneva, Switzerland, 17 September 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug...
Addex Therapeutics First Half 2012 Financial results
Geneva, Switzerland, 22 August 2012 – Addex Therapeutics...
Addex Therapeutics First Half 2012 Financial Results Next Wednesday
Geneva, Switzerland, 20 August 2012
Positive Early Results for Addex Parkinson's Drug Dipraglurant Spur Hopes for Deal
In a small, short Phase IIa study, an oral inhibitor of mGluR5 proved effective at reducing dyskinesia caused by levodopa.
- Seminal Research Provides Greater Insight into the Role of Selective mGluR4 Modulation on Motor Symptoms
Addex to Present Phase 2a Dipraglurant Data at Movement Disorder Society’s International Congress
Geneva, Switzerland, 18 June 2012 -
Geneva, Switzerland, 5 June 2012 –
Addex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder
- Program on track for IND filing before end of 2012
- GABA-BR PAM compounds have potential in several major Indications
Geneva,...
- All key objectives achieved
- Safety and tolerability demonstrated
Addex expects data from dipraglurant trial
23 Feb 2012 MedNous - Addex Pharmaceuticals Ltd expects to report top-line data at the end of March for its lead allosteric modulator that is being
developed to treat patients with Parkinson’s disease who experience dyskinesia...
Addex changes name to Addex Therapeutics
Geneva, Switzerland, 21 March 2012 - Addex Pharmaceuticals (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today...
Addex Pharmaceuticals Reports 2011 Financial Results
Financial Highlights
- Cash and cash equivalents of CHF36.1 million at 31 December 2011
- Cash can fund operations through to 3Q 2013
- Restructuring and pipeline...
New Addex CEO wants to prioritize pipeline quickly
Addex Pharmaceuticals’ new CEO Dr Bharatt Chowrira says he feels a sense of urgency to get on with decision-making at the allosteric modulation-focused Swiss company.
Refining GPCR Discovery Approaches
Emerging Platforms Afford Timelines More Comparable to Those for Soluble Targets.
Structures May Not Solve Everything
This week’s C&EN cover story is about how X-ray crystal structures of G-protein coupled receptors (GPCRs) help the hunt for new drugs. GPCRs are already a major target for drugs (if not the most popular drug target), but until...
Addex's return to basics strategy sees 2 drugs entering Phase II studies this month
BERLIN, March 14 (APM) - Swiss biotech Addex seems to have turned the corner after the failure of its lead compound during Phase II testing at the end of 2009, with two compounds entering Phase II studies within the next few...
BioCentury This Week: Katie Hood discusses funding Parkinson's disease research
BioCentury Washington Editor Steve Usdin recaps that disease groups provide urgency, a unique perspective on risk and a reminder that patients still demand drugs in an era of healthcare cost-cutting.
Addex Pharma wins EuropaBio's Most Innovative Biotech SME Award 2010
Brussels - Video coverage from the event.
Addex wins EuropaBio’s European Biotech SME Award
Geneva/Brussels – Swiss biotech company Addex Pharmaceuticals S.A. is the first winner of EuropaBio’s new ”Most Innovative European Biotech SME Award”.
Therapeutic focus - Parkinson's dyskinesia treatments making progress
The cornerstone of Parkinson’s disease treatment, levodopa, is an effective yet tainted drug - eventually causing side effects as debilitating as the disease it treats.
Glutamate Modulation as Parkinson’s Therapy
Glutamate is a critical neurotransmitter that is involved in a multitude of biological functions and disease processes.
While three companies are targeting metabotropic glutamate receptor subtype 5 to treat levodopa-induced dyskinesia, Addex Pharmaceuticals Ltd. was the first to publicly report significant preclinical effects on both the chorea...
Addex Extends Its Runway With CHF 20 Million Investment By BVF
Less than a year after halting its lead program due to liver toxicity signals, Addex Pharmaceuticals has lined up two new sources of financing in two weeks and plans to go forward with a pair of Phase II trials for its new lead...
Actor’s charity to back Swiss drug trial
A Switzerland based pharmaceutical company has turned to a US charity to support its drug development programme as it diversifies fundraising away from a shrinking pool of private investors during the economic slowdown.
The Pink Sheet Daily: Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side
The Michael J. Fox Foundation awarded Addex Pharmaceuticals $900,000 to help pay for a Phase II study testing its mGLuR5 modulator ADX48621 for treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID), the company...
Addex makes plans to move mGluR2 antagonist into clinical trials for Alzheimer's disease
Addex has announced plans to move an mGluR2 antagonist into Phase I trials for Alzheimer's disease (AD) in around a year.
Special Report: Health breakthroughs of the decade
Allosteric modulation listed as a top breakthrough
Rhythm and Blues: The Case for Allosteric Modulators
Switzerland’s Addex Pharmaceuticals rides optimism after drug setback.
Scrappy Addex Has A Plan For Reviving Faith In Its Allosteric Modulators
Addex Pharmaceuticals pulled out all the stops to inspire confidence in its allosteric modulator platform during its R&D day May 11, with presentations designed to demonstrate the breadth of its discovery and development...